ABCL News & Events

JonesResearch notes that Vistagen (VTGN) received an FDA "Study May Proceed" letter enabling further Phase 2 development of intranasal refisolone for menopausal vasomotor symptoms, also known as hot flashes, in the U.S. While refisolone's prior Phase 2a topline efficacy on hot-flash frequency "appears encouraging," the firm would interpret these results "with some caution," the analyst tells investors. If AbCellera's (ABCL) ABCL635 shows clean safety without any hepatic signals and target engagement comparable to Veohah/Lynkuet, the firm would believe the product "will be deemed very competitive," adds the analyst, who reiterates Buy rating and $11 price target on AbCellera shares ahead of Phase 1 update due on May 11.

Reports FY25 revenue $75.1M vs. $28.8M last year. "In 2025, AbCellera successfully delivered on all its corporate priorities, transitioned to a clinical-stage biotech company, and ended the year with approximately $700 million in available liquidity to execute on our strategy," said Carl Hansen, Ph.D., founder and CEO of AbCellera. "We entered 2026 with a fully built platform, a growing pipeline with multiple potential first-in-class programs and important near-term clinical readouts, and sufficient liquidity to fund well beyond the next three years of pipeline investments."